9 results on '"Michaela Breitsamer"'
Search Results
2. Pharmacological Modulation of the Psychiatric Risk Factor FKBP51 Alters Efficiency of Common Antidepressant Drugs
- Author
-
Max L. Pöhlmann, Alexander S. Häusl, Daniela Harbich, Georgia Balsevich, Clara Engelhardt, Xixi Feng, Michaela Breitsamer, Felix Hausch, Gerhard Winter, and Mathias V. Schmidt
- Subjects
FKBP51 ,fkbp5 ,anxiety ,depression ,stress ,antidepressant ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Despite a growing body of research over the last few decades, mental disorders, including anxiety disorders or depression, are still one of the most prevalent and hardest to treat health burdens worldwide. Since pharmacological treatment with a single drug is often rather ineffective, approaches such as co-medication with functionally diverse antidepressants (ADs) have been discussed and tried more recently. Besides classical ADs, there is a growing number of candidate targets identified as potential starting points for new treatment methods. One of these candidates, the FK506 binding protein 51 (FKBP51) is linked to a number of psychiatric disorders in humans. In this study, we used SAFit2—a newly developed modulator of FKBP51, which has shown promising results in rodent models for stress-related disorders delivered in a depot formulation. We combined SAFit2 with the commonly prescribed selective serotonin reuptake inhibitor (SSRI) escitalopram and performed basic behavioral characterization in a mouse model. Remarkably, co-application of SAFit2 lowered the efficacy of escitalopram in anxiety-related tests but improved stress coping behavior. Given the fact that mental diseases such as anxiety disorders or depression can be divided into different sub-categories, some of which more or less prone to stress, SAFit2 could indeed be a highly beneficial co-medication in very specific cases. This study could be a first, promising step towards the use of FKBP51 modulators as potent and specific enhancers of AD efficiency for subclasses of patients in the future.
- Published
- 2018
- Full Text
- View/download PDF
3. Primary and Secondary Binding of Exenatide to Liposomes
- Author
-
Gerhard Winter, Anja Stulz, Michaela Breitsamer, and Heiko Heerklotz
- Subjects
Phosphatidylglycerol ,chemistry.chemical_classification ,0303 health sciences ,Liposome ,Microscale thermophoresis ,Biophysics ,Tryptophan ,Phospholipid ,Phosphatidylglycerols ,Isothermal titration calorimetry ,Peptide ,Articles ,Calorimetry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Membrane ,chemistry ,Liposomes ,Exenatide ,Peptides ,Phospholipids ,030217 neurology & neurosurgery ,030304 developmental biology - Abstract
The interactions of exenatide, a Trp-containing peptide used as a drug to treat diabetes, with liposomes were studied by isothermal titration calorimetry (ITC), tryptophan (Trp) fluorescence, and microscale thermophoresis measurements. The results are not only important for better understanding the release of this specific drug from vesicular phospholipid gel formulations but describe a general scenario as described before for various systems. This study introduces a model to fit these data on the basis of primary and secondary peptide-lipid interactions. Finally, resolving apparent inconsistencies between different methods aids the design and critical interpretation of binding experiments in general. Our results show that the net cationic exenatide adsorbs electrostatically to liposomes containing anionic diacyl phosphatidylglycerol lipids (PG); however, the ITC data could not properly be fitted by any established model. The combination of electrostatic adsorption of exenatide to the membrane surface and its self-association (Kd = 46 μM) suggested the possibility of secondary binding of peptide to the first, primarily (i.e., lipid-) bound peptide layer. A global fit of the ITC data validated this model and suggested one peptide to bind primarily per five PG molecules with a Kd ≈ 0.2 μM for PC/PG 1:1 and 0.6 μM for PC/PG 7:3 liposomes. Secondary binding shows a weaker affinity and a less exothermic or even endothermic enthalpy change. Depending on the concentration of liposomes, secondary binding may also lead to liposomal aggregation as detected by dynamic light-scattering measurements. ITC quantifies primary and secondary binding separately, whereas microscale thermophoresis and Trp fluorescence represent a summary or average of both effects, possibly with the fluorescence data showing somewhat greater weighting of primary binding. Systems with secondary peptide-peptide association within the membrane are mathematically analogous to the adsorption discussed here.
- Published
- 2020
- Full Text
- View/download PDF
4. Do interactions between protein and phospholipids influence the release behavior from lipid-based exenatide depot systems?
- Author
-
Heiko Heerklotz, Michaela Breitsamer, Anja Stulz, and Gerhard Winter
- Subjects
Membrane permeability ,Lipid Bilayers ,Phospholipid ,Pharmaceutical Science ,02 engineering and technology ,030226 pharmacology & pharmacy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,medicine ,Lipid bilayer ,POPC ,Phospholipids ,Membranes ,Microscale thermophoresis ,Proteins ,Phosphatidylglycerols ,General Medicine ,Permeation ,021001 nanoscience & nanotechnology ,Lipids ,Drug Liberation ,Kinetics ,Membrane ,chemistry ,Delayed-Action Preparations ,Phosphatidylcholines ,Biophysics ,Exenatide ,Peptides ,0210 nano-technology ,Gels ,Biotechnology ,medicine.drug - Abstract
The release mechanism for proteins and peptides from vesicular phospholipid gels (VPGs) is very complex. Drug release proceeds via a combination of erosion of the gel and diffusion of the drug out of it. This diffusion can be retarded by a slow permeation of the drug across the lipid bilayers in the gel as well as by its direct binding or adsorption to the lipid bilayers. Finally, the viscosity and homogeneity of the formulation may affect the release behavior. So far a direct correlation between one of these parameters and the release kinetics is not possible. In the present study, we aimed to investigate the contribution of drug-membrane interactions to the release kinetics of exenatide from differently composed VPGs (POPC, POPG and mixtures of both). To this end, in vitro release of exenatide as well as in vitro release of the phospholipids was monitored. Binding affinities were determined by microscale thermophoresis (MST). The sustained release behavior of exenatide could not simply be correlated to high viscosity of the VPG formulation. Release of exenatide from VPGs of anionic membranes containing POPG proceeded with a half-life of the order of 5 days and it seems to be controlled by the erosion of the gel. Its rate is unaffected by the initial pH inside the gel, independently of the strong impact of pH on exenatide binding to the membrane. At pH 4.5, exenatide is cationic and binds to membranes containing anionic POPG with a high affinity (Kd ≈ 10–30 µM). No high affinity membrane binding of exenatide is detected in this at pH 7.4, where exenatide is anionic, and to zwitterionic membranes composed of POPC. Exenatide release from the latter has a significantly longer half-life of 30 to 55 days. That means, these VPGs are much more resistant to erosion and show a very slow diffusional release. In this case, diffusion should be slowed down by the barrier function of the membranes rather than membrane affinity. In conclusion, erosion of the VPG matrix and membrane permeability of the drug are the major parameters influencing the release of exenatide from VPGs of POPC-POPG, whereas drug binding to the membranes had a minor effect only.
- Published
- 2019
- Full Text
- View/download PDF
5. Needle-Free Injection of Vesicular Phospholipid Gels—A Novel Approach to Overcome an Administration Hurdle for Semisolid Depot Systems
- Author
-
Michaela Breitsamer and Gerhard Winter
- Subjects
medicine.medical_specialty ,food.ingredient ,Biocompatibility ,Swine ,Depot ,Phospholipid ,Pharmaceutical Science ,02 engineering and technology ,030226 pharmacology & pharmacy ,Gelatin ,Pig skin ,03 medical and health sciences ,chemistry.chemical_compound ,Drug Delivery Systems ,0302 clinical medicine ,food ,Lecithins ,medicine ,Animals ,Humans ,Erythropoietin ,Phospholipids ,Low stress ,Chemistry ,021001 nanoscience & nanotechnology ,Needle Free Injection ,Surgery ,Needles ,Delayed-Action Preparations ,Full thickness ,0210 nano-technology ,Gels ,Biomedical engineering - Abstract
Vesicular phospholipid gels (VPGs) are depot formulations for the sustained release of drugs which are characterized by a high amount of phospholipids in the formulation. They consist of physiological excipients only and therefore display high biocompatibility. Their manufacture is simple, cheap, solvent free, and ideal for the processing of proteins and peptides because of the low stress on the molecule, for example, by elevated temperatures. One major hurdle of VPGs is their high viscosity which makes them hard to almost impossible to inject with conventional, thin needles used for subcutaneous administration. However, so far no data are published to overcome this administration challenge. In the present study, needle-free injection was investigated and successfully applied as a technology for the easy and elegant administration of VPGs. VPGs with different phospholipid content were injected with a Biojector 2000 into gelatin blocks and full thickness pig skin postmortem as in vitro models and the injection depth was determined after injection. The release behavior was tested after shearing the VPG with the device to evaluate the effect of shearing on the drug release from the formulation. No differences were observed when compared to an ejection with needle and syringe.
- Published
- 2017
- Full Text
- View/download PDF
6. P.223 The role of the psychiatric risk factor FKBP51 in mediating the effects of chronic stress during early life
- Author
-
Gerhard Winter, Lotte van Doeselaar, Felix Hausch, J. Bordes, M. L. Poehlmann, Alon Chen, Mathias V. Schmidt, Aron Kos, Michaela Breitsamer, Clara Engelhardt, and L. Brix
- Subjects
Pharmacology ,medicine.medical_specialty ,business.industry ,Early life ,Psychiatry and Mental health ,Neurology ,medicine ,Pharmacology (medical) ,Chronic stress ,Neurology (clinical) ,Risk factor ,Psychiatry ,business ,Biological Psychiatry - Published
- 2020
- Full Text
- View/download PDF
7. Vesicular phospholipid gels as drug delivery systems for small molecular weight drugs, peptides and proteins: State of the art review
- Author
-
Gerhard Winter and Michaela Breitsamer
- Subjects
Drug ,Biocompatibility ,media_common.quotation_subject ,Phospholipid ,Pharmaceutical Science ,02 engineering and technology ,030226 pharmacology & pharmacy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Drug Delivery Systems ,In vivo ,Animals ,Phospholipids ,media_common ,Liposome ,Proteins ,State of the art review ,021001 nanoscience & nanotechnology ,Molecular Weight ,chemistry ,Drug delivery ,Biophysics ,0210 nano-technology ,Drug carrier ,Peptides ,Gels - Abstract
Lipid-based drug delivery has been investigated for a long time when it comes to liposomes and solid-lipid implants or solid-lipid nanoparticles. The promising, characteristic properties of these systems have led to the development of newer lipid-based drug delivery systems for the sustained release of drugs like liposomes for sustained delivery of substances, DepoFoam™ technology, phospholipid-based phase separation gels and vesicular phospholipid gels. Vesicular phospholipid gels (VPGs) are highly concentrated, viscous dispersions of high amounts of phospholipids in aqueous drug solution. The easy, solvent-free manufacturing process, high biocompatibility and various applications, as depot formulation for the sustained delivery of drugs and as a storage form of small unilamellar vesicles make VPGs highly attractive as drug carriers. Over the last years, the solvent free preparation process has advanced from high pressure homogenization to dual centrifugation (DC). Thereby a very simple one step process has been established for the preparation of VPGs. The semisolid VPG was first described in 1997 by Brandl et al. Since then, many formulations have been developed, encapsulating small molecular weight drugs like 5-FU (2003), cetrorelix (2005), cytarabine (2012) and exenatide (2015). In 2010, the first pharmaceutical protein, erythropoietin, was encapsulated in VPGs and sustained release of the substance was shown in vitro. In 2015, G-CSF was encapsulated in VPGs and tested in vivo for rotator cuff repair in a rat model and for PEGylated IFN-β-1b sustained release from vesicular phospholipid gels was demonstrated in vitro. Further, a very elegant administration technique for VPGs via needle-free injection was established. However this promising drug delivery system does still leave space for improvement and optimization. This review summarizes information about lipid-based depot systems in general and focuses on the historical development of VPGs. It emphasizes the advantages and drawbacks of VPGs as drug delivery device. Additionally, novel preparation methods and applications of VPGs will be discussed. A focus will be set on delivery of pharmaceutical proteins and peptides.
- Published
- 2018
8. Stress-responsive FKBP51 regulates AKT2-AS160 signaling and metabolic function
- Author
-
Xixi Feng, Felix Hausch, Marily Theodoropoulou, Christiana Labermaier, Marcelo Paez-Pereda, Kathrin Hafner, Matthias H. Tschöp, Andrés Uribe-Mariño, Nils C. Gassen, Carine Dournes, Michaela Breitsamer, Christian Namendorf, Tianqi Mao, Carola W. Meyer, Stoyo Karamihalev, Theo Rein, Gerhard Winter, Sara Santarelli, Manfred Uhr, Max L. Pöhlmann, Alexander S. Häusl, Alon Chen, Georgia Balsevich, and Mathias V. Schmidt
- Subjects
0301 basic medicine ,Male ,Science ,Glucose uptake ,Muscle Fibers, Skeletal ,General Physics and Astronomy ,Biological Transport, Active ,Carbohydrate metabolism ,Diet, High-Fat ,Weight Gain ,Models, Biological ,General Biochemistry, Genetics and Molecular Biology ,Article ,Tacrolimus Binding Proteins ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Insulin resistance ,Stress, Physiological ,medicine ,Glucose homeostasis ,Animals ,Phosphorylation ,lcsh:Science ,Mice, Knockout ,Multidisciplinary ,Glucose Transporter Type 4 ,biology ,Chemistry ,GTPase-Activating Proteins ,Glucose transporter ,Skeletal muscle ,General Chemistry ,medicine.disease ,3. Good health ,Cell biology ,Mice, Inbred C57BL ,Insulin receptor ,030104 developmental biology ,medicine.anatomical_structure ,Glucose ,biology.protein ,lcsh:Q ,Signal transduction ,Proto-Oncogene Proteins c-akt ,030217 neurology & neurosurgery ,Signal Transduction - Abstract
The co-chaperone FKBP5 is a stress-responsive protein-regulating stress reactivity, and its genetic variants are associated with T2D related traits and other stress-related disorders. Here we show that FKBP51 plays a role in energy and glucose homeostasis. Fkbp5 knockout (51KO) mice are protected from high-fat diet-induced weight gain, show improved glucose tolerance and increased insulin signaling in skeletal muscle. Chronic treatment with a novel FKBP51 antagonist, SAFit2, recapitulates the effects of FKBP51 deletion on both body weight regulation and glucose tolerance. Using shorter SAFit2 treatment, we show that glucose tolerance improvement precedes the reduction in body weight. Mechanistically, we identify a novel association between FKBP51 and AS160, a substrate of AKT2 that is involved in glucose uptake. FKBP51 antagonism increases the phosphorylation of AS160, increases glucose transporter 4 expression at the plasma membrane, and ultimately enhances glucose uptake in skeletal myotubes. We propose FKBP51 as a mediator between stress and T2D development, and potential target for therapeutic approaches., Stress is recognized as risk factor for the development of type 2 diabetes. Here Balsevich et al. show that the stress responsive co-chaperone FKBP5 regulates glucose metabolism in mice by modulating AS160 phosphorylation, glucose transporter expression and muscle glucose uptake.
- Published
- 2017
9. Unraveling the functional contribution of FKBP-51 in monoaminergic brain areas to stress vulnerability in mice
- Author
-
M. L. Poehlmann, D. Harbich, Jan M. Deussing, Xixi Feng, Alexander S. Häusl, Gerhard Winter, Michaela Breitsamer, Jakob Hartmann, Bianca Schmid, Felix Hausch, Nina Dedic, and Mathias V. Schmidt
- Subjects
Pharmacology ,Psychiatry and Mental health ,FKBP ,Neurology ,Monoaminergic ,Stress vulnerability ,Pharmacology (medical) ,Neurology (clinical) ,Biology ,Neuroscience ,Biological Psychiatry - Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.